ABIVAX Société Anonyme (NASDAQ:ABVX) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of ABIVAX Société Anonyme (NASDAQ:ABVX) have been given a consensus recommendation of “Moderate Buy” by the seven ratings firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $36.50.

Separately, Laidlaw assumed coverage on ABIVAX Société Anonyme in a report on Monday, July 29th. They issued a “buy” rating and a $48.00 price objective for the company.

Hedge Funds Weigh In On ABIVAX Société Anonyme

Large investors have recently made changes to their positions in the business. BNP Paribas Financial Markets bought a new position in ABIVAX Société Anonyme during the first quarter worth about $81,000. Capstone Investment Advisors LLC bought a new position in shares of ABIVAX Société Anonyme in the fourth quarter valued at approximately $618,000. Ghisallo Capital Management LLC bought a new position in shares of ABIVAX Société Anonyme in the fourth quarter valued at approximately $642,000. Kennedy Capital Management LLC raised its stake in shares of ABIVAX Société Anonyme by 35.3% in the first quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company’s stock valued at $1,718,000 after acquiring an additional 31,331 shares during the last quarter. Finally, Rosalind Advisors Inc. bought a new position in shares of ABIVAX Société Anonyme in the first quarter valued at approximately $5,411,000. Institutional investors and hedge funds own 47.91% of the company’s stock.

ABIVAX Société Anonyme Price Performance

Shares of NASDAQ:ABVX opened at $11.30 on Friday. ABIVAX Société Anonyme has a twelve month low of $7.99 and a twelve month high of $17.02. The company has a quick ratio of 4.08, a current ratio of 3.04 and a debt-to-equity ratio of 0.48. The company has a 50 day moving average of $11.84 and a 200-day moving average of $13.36.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.